Background-Human
O rthotopic heart transplantation remains the only viable option for many patients suffering from end-stage ischemic and nonischemic cardiomyopathies. [1] [2] [3] Transplant coronary artery disease (TCAD) accounts for the great majority of late graft loss. [1] [2] [3] This disease entity affects up to 70% to 80% of patients if examined by intravascular ultrasound by year 2 and will be seen angiographically in up to 50% of patients. 3 Chemokines have been linked to the development of acute rejection episodes and TCAD in animal studies and some human studies. 4 -9 The CCR5 chemokine ligands RANTES/ CCL5, Mip-1␣/CCL3, and Mip-1␤/CCL4 and the CXCR3 chemokine ligands ITAC/CXCL11, MIG/CXCL9, and IP-10/ CXCL10 are found in proinflammatory states and are chemoattractant for monocytes and Th1 lymphocytes. 10, 11, [12] [13] [14] Increased levels of IP-10/CXCL10 were found in a murine model of TCAD. 9 In humans, MIG/CXCL9 and IP-10/ CXCL10 have been associated with the development of acute rejection episodes. [15] [16] [17] It is our hypothesis that the CCR5 and CXCR3 chemokine ligands are involved in the pathogenesis of TCAD.
Methods

Patient Population
Patients who had undergone transplantation and had severe 2-to 3-vessel TCAD (defined as Ն2 vessels with Ͼ50% angiographic stenosis; nϭ15) and long-term, disease-free survivors of transplantation (defined as angiographic absence of disease at least 8 years after transplantation; nϭ15) were enrolled during annual right and left heart catheterization (Table) . Ideally, intravascular ultrasound should be performed on all patients; however, this was not practical. At enrollment, 10 mL of whole blood was taken from the femoral artery, placed in sodium heparin tubes on ice, and spun down at 4°C. The plasma was stored at Ϫ80°C until analysis. The Office for the Protection of Research Subjects and Medical Institutional Review Board approved the protocol, and all subjects gave written, informed consent.
ELISA
CCR5 and CXCR3 chemokine ligands were quantified by using a modification of the double-ligand method, as previously described, with a sensitivity of 50 pg/mL or higher. 18 The polyclonal antibodies used were anti-human RANTES/CCL5 (R&D Systems, Minneapolis, Minn), anti-human Mip-1␣/CCL3, and Mip-1␤/CCL4 (RMS Laboratory) for the CCR5 ligands, and anti-human MIG/CXCL9 (R&D Systems), ITAC/CXCL11, and IP-10/CXCL10 (PeproTech, Rocky Hills, NJ) for the CXCR3 ligands.
Immunohistochemistry
Paraffin blocks of coronary arteries were obtained from transplanted hearts at the time of death or retransplantation for TCAD. Paraffinembedded tuberculosis granulomas from lung specimens were used as a positive control for immunolocalization of MIG/CXCL9, ITAC/ CXCL11, and IP-10/CXCL10. Slides were initially incubated at 60°C and then immersed in sequential baths of xylene, 100%, 95%, and 70% ethanol. The slides were subsequently placed in 3% H 2 O 2 in methanol and then washed 1ϫ with PBS. Antigen retrieval was performed with the use of a citrated buffer. Normal horse serum (3%) or normal goat serum (3%) was used for the blocking agent for CXCR3, MIG/CXCL9, IP-10/CXCL10, and ITAC/CXCL11. The tissue was subsequently incubated at room temperature with mouse anti-CXCR3 antibody (Pharmingen, San Diego, Calif), mouse anti-MIG/CXCL9 (R&D Systems), goat anti-IP-10/CXCL10, and rabbit anti-ITAC/CXCL11 antibody (PeproTech, Inc, Rocky Hill, NJ). The secondary antibody (Vector Laboratory, Inc, Burlingame, Calif) was made up in 1% of the corresponding blocking serum (normal horse serum or normal goat serum). For staining, horseradish peroxidasebound avidin-biotin was applied, and the slides were developed with DAB solution (Vector Laboratory, Inc). The slides were examined and interpreted by our cardiac pathologist (M.C.F.).
Statistical Analysis
Statistical analysis was carried out with the use of StatView.
Nonparametric analysis was used to analyze the data. For comparison of the 3 groups, Kruskal-Wallis analysis was used, and for comparisons between groups, Mann-Whitney analysis was performed.
Results
ELISA
The CCR5 chemokine ligands were not associated with TCAD and were not studied further ( Figure 1A. ). Of the CXCR3 chemokine ligands studied, only ITAC/CXCL11 was found to be elevated in patients with TCAD compared with control subjects (Control) and survivors without TCAD Middle Eastern ⅐ ⅐ ⅐ 1 (7) Ejection fraction 57. accelerated atherosclerosis. 1-3 However, unlike atherosclerosis seen in native coronary arteries, TCAD is a concentric, diffuse disease involving the distal coronary arteries and small branches. Mortality rate after the initial diagnosis of TCAD is Ͼ40% after 2 years. 16 It is important, therefore, to prevent TCAD and prolong the life of the original transplant. Histologically, mononuclear cell inflammation, fibrocellular intimal hyperplasia, and endothelial damage characterize TCAD. [1] [2] [3] Chemokines have been implicated in acute and chronic solid organ rejection, and the CCR5 and CXCR3 chemokine ligands have been most closely associated with cardiac allograft rejection. 14, [18] [19] [20] In a recent human study in which endomyocardial biopsies were used, elevated levels of ITAC/CXCL11 and IP-10/CXCL10 mRNA were found to be associated with TCAD, and elevated levels of IP-10/CXCL10 and MIG/CXCL9 mRNA were found during episodes of acute rejection. 14 We demonstrate elevated plasma protein levels of the CXCR3 chemokine ligand, ITAC/CXCL11, in patients with severe TCAD. Immunohistochemical studies localized ITAC/CXCL11 to the endothelial surface of TCAD lesions and demonstrated the presence of CXCR3 ϩ mononuclear cells within these lesions. In contrast, we did not find positive immunostaining for either MIG/CXCL9 or IP-10/ CXCL10. This is the first study demonstrating elevated serum levels and arterial immunohistochemical evidence of ITAC/ CXCL11 involvement in TCAD.
To our knowledge, this is the first study of peripheral blood used to implicate chemokines in the development of TCAD. Several chemokines that have been implicated in animal models of TCAD-namely RANTES/CCL5, IP-10/ CXCL10, and MIG/CXCL9 -were not found to correlate with the presence of TCAD in our study. Most of the studies looking at the CC and CXC chemokines in TCAD have been in animal models of transplant disease. It is unknown if human pathology follows a similar time course or mechanism as the animal models. Also, our study was based on peripheral blood levels, and levels of chemokines other than ITAC/CXCL11 may be diluted to nondetectable levels or may be bound to circulating red blood cells. It is conceivable that direct sampling of the coronary sinus would provide a more accurate profile of chemokine secretion. Future studies with this sampling technique will help elucidate this possibility.
Conclusions
This study, to our knowledge, is the first demonstrating a correlation between circulating chemokine levels and development of TCAD in humans. Of the chemokines studied, only ITAC/CXCL11, a CXCR3 ligand, was associated with TCAD by elevated serum levels and immunohistochemical localization. ITAC/CXCL11 may have a causative role in the pathogenesis of this disease and may provide a way to prospectively identify patients at risk for the development of TCAD. Further prospective trials will be needed to confirm this hypothesis. 
